CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

205029Orig1s000

SUMMARY REVIEW

Primary Medical and Cross-Discipline Team Leader Review

Date	17 July 2014
From	Shari L. Targum, M.D.
Subject	Cross-Discipline Team Leader Review
NDA/BLA #	#205029
Applicant	Belcher Pharmaceuticals
Date of Submission	29 January 2014
PDUFA Goal Date	29 July 2014
Proprietary Name / Established (USAN) names	Epinephrine injection, USP
Dosage forms / Strength	1 mg/mL 1:1000
Proposed Indication(s)	Increase mean arterial blood pressure in hypotension associated with septic shock.
Recommended:	*Approval pending DMEPA review and acceptance of label*

The DMEPA review of revised carton and container labels and insert labeling is pending at this time.

1. Introduction

The applicant has submitted a response to the Agency's Complete Response action for NDA #205029 (see Background, below). This review will address two outstanding issues from the original application review: CMC deficiencies and pediatric information.

2. Background

Epinephrine has been marketed for over 50 years. Epinephrine injection, USP auto-injector (each unit delivers 0.15 mg or 0.3 mg of epinephrine) is approved in the emergency treatment of severe allergic reactions (Type I). However, intravenous epinephrine, while marketed, is not approved for use in septic shock.

In 2006, the Agency began an initiative to remove unapproved drugs from the market and issued the guidance, "Marketed Unapproved Drugs—Compliance Policy Guide (CPG)." The applicant submitted NDA #205029 on December 4, 2012, for approval of epinephrine in septic shock, based on support from published literature [505(b) (2) submission].

However, CMC deficiencies in the review of NDA #205029 led to the issuance of a Complete Response (CR) action (4 October 2013). The applicant proposed a [redacted] However, the CMC review team did not agree and recommended that the product undergo [redacted] In addition, the CMC reviewers do not consider the proposed assays for drug and degradants to be adequately validated for use at release or on stability. (Establishment inspections were also incomplete).

The Agency also did not agree with the applicant's request for a full waiver of pediatric studies; the Agency instead requested that the applicant submit information from all available sources, including literature, in order to appropriately label epinephrine for the pediatric population.

3. CMC/Device

In the current review, the CMC reviewer has recommended approval for NDA 205029. The applicant has agreed to submit long-term storage stability data for three commercial batches for expiration dating extension of the drug product as a post-approval supplement.

- General product quality considerations

In this resubmission, the drug product formulation was revised [redacted] The CMC reviewer considered this [redacted] to be acceptable.

The proposed commercial manufacturing process entails [redacted] The drug product specification was revised for assay to [redacted] and included acceptance limits of no more than [redacted] and [redacted] for [redacted] at release and on stability respectively.

Stability data were provided for one batch of drug product manufactured with revised formulation and manufacturing process stored at long term storage conditions (25°C) up to 9 months. Based on the levels of [redacted] observed on stability, the applicant proposed a shelf-life of [redacted] months for the drug product. However, based on stability data showing that the drug product maintains the critical quality attributes up to 12 months, the CMC reviewer recommended a 12 month shelf-life for the drug product.

- Facilities review/inspection

The Office of Compliance has provided an overall acceptable recommendation for manufacturing and testing facilities for this NDA.

4. Nonclinical Pharmacology/Toxicology

In their review of the original application, the nonclinical pharmacology/toxicology reviewers found the NDA to be approvable; there are no new nonclinical pharmacology/toxicology data.

5. Clinical Pharmacology/Biopharmaceutics

In their review of the original application, the clinical pharmacology/biopharmaceutics reviewers recommended approval of epinephrine based on its effect on mean arterial pressure (MAP) in septic shock patients. The proposed dosing regimen in septic shock patients is 0.05 to 2.0 µg/kg/min continuous intravenous (IV) infusion titrated to achieve a target MAP.

A summary of key features from Dr. Hariharan's review:

- When administered intravenously, epinephrine rapidly disappears from plasma with an effective half-life of < 5 minutes. Time to pharmacokinetic steady state following continuous intravenous (IV) infusion is about 10 minutes.
- Following intravenous (IV) infusion, epinephrine has a quick onset of blood pressure response (< 5 minutes). The time to offset of effect is about 10-15 minutes.
- There is a trend for dose-dependent increase in blood pressure and heart rate with increasing doses of epinephrine (0.001 to 0.2 µg/kg/min) in healthy subjects.
- In septic shock patients, there is an increase in MAP with IV infusions of epinephrine. However, results of a naïve-pooled analysis suggest a high degree of inter-patient variability.
- Intrinsic factors such as age, body weight and disease severity may affect pharmacokinetics of epinephrine. However, due to the rapid onset and offset characteristics, close monitoring, and dose titration to a target response, no dose adjustments are warranted.

6. Clinical Microbiology

The microbiology reviewer recommended approval based on the original submission; there is no new microbiology information.

7. Clinical/Statistical- Efficacy

Dr. Moreschi recommended approval of epinephrine for the treatment of hypotension in septic shock. The basis of her approval recommendation was the consistent increase in mean arterial blood pressure supported by publication-based evidence. Dr. Moreschi had no recommendations for postmarketing requirements or commitments.

Dr. Bai concluded that the literature-based evidence was exploratory. I concur with Dr. Bai, but conclude that the consistent results in different publications over time support a role for epinephrine to increase mean arterial blood pressure in hypotensive patients with septic shock.

8. Safety

In reviewing the original application, Dr. Moreschi used the Twinject label, published literature provided by the sponsor, and references cited in Goodman and Gilman and Ellenhorn's Medical Toxicology to find case reports of the side effects from the use of epinephrine for longer periods of time.

In her review, Dr. Moreschi noted the high background mortality rate in septic shock and the resulting difficulty of calculating deaths from epinephrine use. She has also noted the lack of safety data with prolonged use of intravenous epinephrine. I concur. Intravenous pressors are routinely used in the intensive care unit, under close monitoring and telemetry. Moreover, intravenous epinephrine has a short half-life; thus, the drug can be stopped with rapid disappearance of plasma levels in the event of an adverse effect.

Epinephrine use was associated with palpitations (Illi 1995), tachycardia (Myburgh 2008), and cardiac arrhythmias (Mackie 1991, Brock 2003, Annane 2007) and metabolic effects such as lactic acidosis (Day 1996, Myburgh 2008), increase in blood sugar (Beck 1985) and increase in insulin requirement (Myburgh 2008).

Other events from published literature included: limb ischemia, stroke, myocardial ischemia and infarction, pulmonary edema, renal insufficiency. While these events could have been related to underlying conditions and/or concomitant medications, it is also plausible that these events resulted from epinephrine's pharmacologic effects and appropriate mention should appear in labeling.

9. Advisory Committee Meeting

This application was not presented to an advisory committee.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.